Enhertu shows progression-free survival benefit in lung cancer trial

Daiichi Sankyo and AstraZeneca's Enhertu cut the risk of progression or death by 37% versus pembrolizumab plus chemotherapy in the Phase 3 DESTINY-Lung04 first-line HER2-mutant non-small cell lung cancer trial (HR 0.63). Median progression-free survival was 14.3 months versus 8.3 months, while objective response was 70.0% versus 44.5%. Safety was consistent with Enhertu's known profile, though 20.8% experienced interstitial lung disease/pneumonitis, including four grade 5 events; overall-survival data were not yet formally tested.

Analysis

The investable implication is less the trial readout than the potential migration of Enhertu into an earlier, duration-of-therapy setting. First-line use can materially raise treated-patient years and reinforce Enhertu's position as Daiichi Sankyo's highest-value oncology asset; AZN's absolute earnings sensitivity is smaller given its diversified base. The addressable HER2-mutant NSCLC population is narrow, however, so this alone is unlikely to justify a major AZN multiple rerating absent label breadth or evidence that it displaces treatment across additional biomarker-defined lung cohorts.

The critical valuation constraint is tolerability. A high rate of lung toxicity, including fatal events, gives regulators, physicians and payers a clear reason to restrict use to carefully selected patients or require enhanced monitoring, reducing real-world penetration versus protocol efficacy. Immature survival data also leave open the possibility that progression-free benefit does not convert into a durable survival or quality-of-life advantage; that would limit guideline enthusiasm and weaken the case for first-line reimbursement.

Near term, AZN should outperform large-cap oncology peers modestly on pipeline de-risking, but the cleaner fundamental beneficiary is Daiichi Sankyo (4568 JP), whose earnings and strategic value remain more concentrated in the Enhertu franchise. The contrarian view is that the initial equity reaction should be contained: an already commercialized drug gaining a small biomarker segment has lower incremental NPV than the headline efficacy figures imply, while safety creates a meaningful adoption discount.

Key Decisions for Investors

• Maintain or initiate a modest 1-3 month long AZN position only on post-data weakness; target a 5-8% upside from pipeline de-risking, with a 3-4% stop if regulatory or physician commentary centers on treatment-related pneumonitis rather than efficacy.
• Prefer a 6-18 month long Daiichi Sankyo (4568 JP) versus AZN as the higher-beta expression of Enhertu expansion; size conservatively because franchise concentration magnifies safety and label-risk. Reassess if management does not raise oncology/franchise sales expectations at the next results cycle.
• Do not short Merck (MRK) solely on this result. The affected biomarker population is too limited to move consolidated Keytruda economics; a broader competitive signal would require evidence of share loss in adjacent first-line lung indications.
• Set an alert for regulatory filing language, final overall-survival maturity, and any updated discontinuation or fatal-ILD rates over the next 6-12 months. A restrictive label, no survival trend, or higher real-world pulmonary toxicity would falsify the bullish adoption thesis.